PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28805677-8	2017	In contrast, administration of rat serum albumin (RSA, 0.1-0.5 mg/mL) resulted in a dose-dependent increase in MMP-9 expression and secretion by TECs, which was abolished in the presence of an ERK1/2-specific inhibitor, U0126.	U 0126	220-225	matrix metallopeptidase 9	Rattus norvegicus	111-116	
35001858-9	2022	However, U0126, a kind of inhibitor of MEK, lowered the quantities of phospho-ERK and MMP-9, raised the expression of ZO-1, and suppressed apoptosis.	U 0126	9-14	matrix metallopeptidase 9	Rattus norvegicus	86-91	
28726167-8	2017	Furthermore, B1R activation facilitated the mRNA and protein expressions of MMP-9 in the hemorrhagic tissues, and these increases were blocked by both ERK inhibitor U0126 and NF-kappaB inhibitor PDTC.	U 0126	165-170	matrix metallopeptidase 9	Rattus norvegicus	76-81	
23473787-5	2013	Downregulation of extracellular signal-regulated kinase (ERK) signaling using the ERK inhibitor U0126 and the calcium-channel blocker ketamine inhibited the upregulation of miR-21 expression and MMP9 protein level after cerebral ischemia.	U 0126	96-101	matrix metallopeptidase 9	Rattus norvegicus	195-199	
23774252-7	2013	TNF-alpha-enhanced p42/p44 MAPK, p38 MAPK, JNK1/2, and NF-kappaB (p65) phosphorylation and in vivo binding of p65 to the MMP-9 promoter were inhibited by U0126, SB202190, SP600125, NAC, DPI, or APO.	U 0126	154-159	matrix metallopeptidase 9	Rattus norvegicus	121-126	
23259581-16	2012	Inhibition of the MEK-ERK1/2 pathway by U0126 starting at 6 h post-SAH prevented upregulation of cytokines and MMP-9 in cerebral vessels, and improved neurological outcome.	U 0126	40-45	matrix metallopeptidase 9	Rattus norvegicus	111-116	
23671886-0	2013	The ERK1/2 Inhibitor U0126 Attenuates Diabetes-Induced Upregulation of MMP-9 and Biomarkers of Inflammation in the Retina.	U 0126	21-26	matrix metallopeptidase 9	Rattus norvegicus	71-76	
23671886-5	2013	Intravitreal administration of the ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2 activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and TNF- alpha and upregulated TIMP-1 expression.	U 0126	52-57	matrix metallopeptidase 9	Rattus norvegicus	162-167	
19497125-5	2009	The specific MEK1/2 inhibitor U0126, given intraperitoneal zero or 6 hours after the ischemic event, reduced the infarct volume significantly (11.8 +/- 2% and 14.6 +/- 3%, respectively; P < 0.05), improved neurological function, normalized expression of phosphorylated ERK1/2, and reduced expression of MMP-9 and TIMP-1 in the vessel walls.	U 0126	30-35	matrix metallopeptidase 9	Rattus norvegicus	306-311	
12898704-5	2003	Although PMA increased phosphorylation in all three major MAP kinase pathways (ERK, p38 MAP kinase, and JNK), only inhibition of the ERK pathway by the MEK/ERK inhibitor U0126 (0.1-10 microM) significantly reduced MMP-9 upregulation, even when treatment was delayed for 4 h after PMA exposure.	U 0126	170-175	matrix metallopeptidase 9	Rattus norvegicus	214-219	
17996850-8	2007	U-0126 prevented GSK-3beta inhibition-mediated induction of MMP-9 reporter activity as well as the MMP-9 gene expression.	U 0126	0-6	matrix metallopeptidase 9	Rattus norvegicus	60-65	
17996850-8	2007	U-0126 prevented GSK-3beta inhibition-mediated induction of MMP-9 reporter activity as well as the MMP-9 gene expression.	U 0126	0-6	matrix metallopeptidase 9	Rattus norvegicus	99-104	
18950865-8	2009	The inhibitor of mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway (U0126, 10microM) prevented LTA stimulation of MMP 9 secretion; however, the inhibitors of p38 (SB203580, 10microM) and Jun N-terminal kinase (JNK; SP600125, 10microM) presented any effect.	U 0126	109-114	matrix metallopeptidase 9	Rattus norvegicus	155-160	
12898704-8	2003	But in this case, all three MAP kinase inhibitors (U0126, SB203580, and SP600125) reduced TNFalpha-induced MMP-9 upregulation.	U 0126	51-56	matrix metallopeptidase 9	Rattus norvegicus	107-112	
11698409-7	2002	Activation of the Shc/mitogen-activated protein kinase pathway mediates the induction of MMP-9 in response to NGF, as this response is abrogated in cells expressing a mutant TrkA receptor that does not bind Shc and by pretreatment of cells with the MEK-1 inhibitor, U0126.	U 0126	266-271	matrix metallopeptidase 9	Rattus norvegicus	89-94	
11116048-5	2000	Treatment with either SB203580 (inhibitor of p38 MAPK) or U0126 (inhibitor of the ERK pathway) downregulated the TNF-alpha-induced MMP-9 expression in a dose-dependent manner.	U 0126	58-63	matrix metallopeptidase 9	Rattus norvegicus	131-136	
11116048-7	2000	Furthermore, suboptimal inhibitory concentrations of SB203580 and U0126 together almost completely inhibited the MMP-9 expression.	U 0126	66-71	matrix metallopeptidase 9	Rattus norvegicus	113-118